MARKET

SPPI

SPPI

Spectrum Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.110
+0.040
+1.30%
Opening 12:24 05/11 EDT
OPEN
2.950
PREV CLOSE
3.070
HIGH
3.120
LOW
2.915
VOLUME
911.50K
TURNOVER
--
52 WEEK HIGH
5.24
52 WEEK LOW
2.680
MARKET CAP
484.27M
P/E (TTM)
-2.2681
1D
5D
1M
3M
1Y
5Y
Immuno-oncology Therapy Market Size, Share, Growth,Trends, COVID-19 Analysis and Forecast 2021-2028
pune, India, Thu, 06 May 2021 23:32:16 / Comserve Inc. / -- The global Immuno-oncology Therapy market size is projected to reach US$ 1648.7 million by 2028,...
Comserve · 4d ago
Cancer Immunotherapy Market Profile, Sales, Cost, Profit, Opportunities and Global Industry Analysis By 2027
May 06, 2021 (Heraldkeepers) -- Cancer Immunotherapy Market Insights The rapid application of this therapy by healthcare professionals, and patients and the...
Heraldkeepers · 4d ago
Spectrum Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Corporate Update
Business Wire · 5d ago
Analysts Offer Insights on Healthcare Companies: Spectrum Pharmaceuticals (SPPI) and Mediwound (MDWD)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spectrum Pharmaceuticals (SPPI) and Mediwound (MDWD) with
SmarterAnalyst · 5d ago
Superficial Bladder Cancer Drugs Market Research Reports, Industry Analysis & Business Strategy By 2027
May 05, 2021 (Heraldkeepers) -- The report covers detailed competitive outlook including the market share and company profiles of the key participants...
Heraldkeepers · 6d ago
Micro Chemotherapy Market to Register Incremental Revenue Opportunities During the Forecast Period 2021-2027
May 05, 2021 (Heraldkeepers) -- Market Research Engine has published a new report titled as "Micro Chemotherapy Market Size By Product (Physical Therapy,...
Heraldkeepers · 6d ago
Peripheral T-Cell Lymphoma Treatment Market is Expected to Witness Rapid Growth by 2028 | Pacira Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Inc., Celgene Corporation. among Others
May 04, 2021 (MARKITWIRED via COMTEX) -- According to Non-Hodgkin's Lymphoma Classification Project (CDC), peripheral T-cell lymphoma patients constitute...
Markitwired · 6d ago
Epigenetics Drugs and Diagnostic Technologies Market Research Report: Cagr Status, Industry Growth, Trends, Analysis And Forecasts To 2027
Heraldkeepers · 05/04 15:58
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SPPI. Analyze the recent business situations of Spectrum Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SPPI stock price target is 10.20 with a high estimate of 14.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 259
Institutional Holdings: 105.16M
% Owned: 67.53%
Shares Outstanding: 155.71M
TypeInstitutionsShares
Increased
58
10.78M
New
24
1.16M
Decreased
42
3.22M
Sold Out
20
1.44M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.05%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Independent Director
William Ashton
President/Chief Executive Officer/Director
Joseph Turgeon
Chief Financial Officer/Executive Vice President
Kurt Gustafson
Chief Operating Officer/Executive Vice President
Thomas Riga
Executive Vice President
Francois Lebel
Senior Vice President/Secretary
Keith McGahan
Senior Vice President
Lyndah Dreiling
Director
Nora Brennan
Independent Director
Seth Fischer
Independent Director
Jeffrey Vacirca
Independent Director
Dolatrai Vyas
Independent Director
Bernice Welles
Declaration Date
Dividend Per Share
Ex-Div Date
12/10/2012
Dividend USD 0.15
12/18/2012
About SPPI
Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company operates through developing and commercializing oncology and hematology drug products segment. It focuses on developing ROLONTIS and POZIOTINIB. ROLONTIS is being investigated for the treatment of chemotherapy-induced neutropenia. POZIOTINIB is an oral pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR, HER) Family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.

Webull offers kinds of Spectrum Pharmaceuticals, Inc. stock information, including NASDAQ:SPPI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPPI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SPPI stock methods without spending real money on the virtual paper trading platform.